Slides
Page 1
9M 2026 RESULTS FAES FARMA
Page 2
Table of Contents Highlights and main key figures Results 9M 2026 1/ 3/Business performance2/
Page 3
1/ Highlights and main key figures
Page 4
Highlights for the first 9 months of 2026 4 R&D and Portfolio Financial position HIGHLIGHTS AND KEY FIGURES Business Total revenue +24%, growth driven mainly by the integration of acquisitions and the strong performance of international direct markets. Pharma revenue +24%, with the integration of ophthalmology as a key area. Bilastine was impacted by the expiry of patent protection in Japan, in line with forecasts. EBITDA +17%, including organisational restructuring costs at SIFI and Edol. Excluding these costs, growth would have been 20%. Other The integration of SIFI and Edol is progressing on schedule, maintaining business continuity and strong performance whilst making headway in optimising the organisational structure. The merger of SIFI Ibérica has been completed. The solid performance of the business allows the debt-to-EBITDA ratio to be maintained in line with the company’s targets and projected ranges (<2 times EBITDA) and ensures an adequate level of liquidity. Solid progress in industrial consolidation, with the relocation to Derio proceeding as planned. Approval of the reimbursement status for Akantior in Italy. Approval in Europe of Mesalazine 1500 mg tablets. Completion of recruitment for the pivotal efficacy clinical trial of Mesalazine Granules. Boost to growth in ophthalmology through the expansion of the development pipeline and the submission of new regulatory dossiers for multiple products in Europe and Latin America. Agreement with Dongkook Pharmaceutical for the commercialisation in Latin America of a licence for the treatment of benign prostatic hyperplasia.
Page 5
Key figures for 9M 2026 HIGHLIGHTS AND KEY FIGURES Revenue EBITDA PBT Net Profit 5 563.5 M€ 24% 124.4 M€ 17% 87.3 M€ +1% 74.3 M€ 1%
Page 6
2/ Business performance 9M 2026
Page 7
Revenue by portfolio segment BUSINESS PERFORMANCE 9M 2026 Bilastine Calcifediol Mesalazine Bilastine is experiencing the expected impact in Japan associated with the expiry of the molecule’s patent protection. Momentum in Latin America remains positive, with growth of +9%. Sales of calcifediol continue to grow strongly +19%, confirming the positive performance of international markets in both direct sales and licensing. Mesalazine has grown by +10% over these nine months, supported by strong performance in Latin America and Portugal. 94.3 55.6 18.7 Ophthalmology With the integration of SIFI and Edol, ophthalmology has established itself as one of the group’s key areas, now accounting for 17% of total revenue.96.8 Millions of € 7 Farma top 3 moléculas 30% Oftalmología 17% Other Pharma 41% Nutrición y Salud Animall 12% Millions of euros 9M 2026 9M 2025 % Pharmaceuticals 486.5 392.7 24% Top 3 pharmaceutical molecules 168.6 175.1 (4%) Ophthalmology* 96.8 13.2 - Other Pharma 221.1 204.4 8% Animal Nutrition and Health 68.6 58.3 18% Other** 8.4 3.0 176% Group total 563.5 454.0 24% * Ophthalmology includes SIFI + Edol (ex derma) ** Non-commercial revenue and exchange rate impact Figures are rounded
Page 8
Revenue by business area BUSINESS PERFORMANCE 9M 2026 8 Iberia Pharma 34% International Pharma (ex licences) 39% Pharma Licences 15% Animal Nutrition and Health 12% Millions of euros 9M 2026 9M 2025 % Pharmaceuticals 486.5 392.7 24% Pharma Iberia 186.6 170.1 10% Pharma International (without licences) 216.6 123.4 76% Pharma Licences 83.3 99.2 (16%) Animal Nutrition and Health 68.6 58.3 18% Other* 8.4 3.0 176% Group total 563.5 454.0 24% * non-commercial revenue and exchange rate impact Figures are rounded
Page 9
Pharma Iberia The prescription business remains stable, supported by the strong performance of calcifediol and the respiratory product range, offsetting a more challenging environment for bilastine. Healthcare and Consumer (-2%) The momentum of priority brands is performing well, against a less favourable trend in the rest of the portfolio, which we expect to moderate towards the end of the year SPAIN PORTUGAL Faes Farma Portugal’s business grew by +9%, driven by the performance of mesalazine and calcifediol in the prescription segment, alongside strong performance in Healthcare, which is regaining market momentum. Meanwhile, sales at Laboratorio Edol totalled €27.8 million. -1% 49% BUSINESS PERFORMANCE 9M 2026 €186.6 million 10% Revenue 9M 2026 133.3 131.7 9M 2025 9M 2026 24.9 27.2 27.8 9M 2025 9M 2026 Spain Portugal 9 Edol Figures are rounded 11.9
Page 10
Pharma International BUSINESS PERFORMANCE 9M 2026 Latin America continues to perform strongly, reaffirming its growth momentum. Most markets are recording very significant growth: Colombia (+14%), Ecuador (+15%), Peru (+13%) and Central America (+21%), with Mexico (+37%) standing out in particular as it continues to consolidate its position as one of the main drivers of regional performance. Meanwhile, Chile (+7%) has managed to regain momentum following a more challenging start to the financial year. Growth is underpinned by the strong performance of strategic products, particularly bilastine and calcifediol. LATAM 18% ROW 9% ROW (excluding SIFI) grew by +9% , confirming solid and sustained growth underpinned by strong sell-out performance in most markets. The Gulf region, meanwhile, remains under pressure from the geopolitical context, but is gradually stabilising. €216.6 million 76% Revenue 9M 2026 77.6 91.3 9M 2025 9M 2026 39.2 42.6 82.6 9M 2025 9M 2026 LATAM Rest of the World 10 SIFI SIFI contributed over €82 million to the nine-month period, with very strong performance in markets such as Italy and Spain. SIFI Figures are rounded 6.6
Page 11
Pharma Licences BUSINESS PERFORMANCE 9M 2026 Bilastine has been affected by the expected launch of generics in Japan. The licence’s performance in other regions remains positive, with solid results in Europe – particularly in Eastern European countries – and notable growth in the Asia- Pacific region. BILASTINE LICENCE -23% OTHER LICENCES 6% Among other licences, calcifediol has established itself as the main driver with year-on-year growth of +21%, showing positive momentum across all markets and particularly following the most recent launches in France, Greece and Australia. Mesalazine has reversed the trend seen in the first half of the year and recorded growth of +8%, offsetting timing between sell-in and sell-out. €83.3 million -16% Revenue 9M 2026 Bilastine licence 22.9 24.3 9M 2025 9M 2026 Other licences 11 76.3 59.0 9M 2025 9M 2026 Figures are rounded
Page 12
Farm Faes BUSINESS PERFORMANCE 9M 2026 Solid business performance, driven primarily by the consolidation of ISF as the main growth driver, increased activity with major clients, an improved product mix and operational efficiency. This area includes a small veterinary division resulting from the integration of Laboratorio Edol. €68.6 million 18% Revenue 9M 2026 58.3 68.6 9M 2025 9M 2026 FARM Faes 12 Figures are rounded
Page 13
3/ Results 9M 2026
Page 14
9M 2026 RESULTS Income statement for 9M 2026 14 REVENUE EXPENSES EBITDA The trend in expenses reflects the expansion of the scope of operations and business growth, while maintaining disciplined management of the cost base. The increase in personnel expenses is due to the new scope of operations, the restructuring of SIFI and Edol in the first quarter, and strategic hiring. The increase in is linked to business growth and, to a large extent, to the amortisation of intangible assets recognized in connection with the recent acquisitions and integrations of SIFI and Edol. Financial expenses are in line with expectations. Active management of the cash position partially offsets the rise in interest rates and the impact of Latin American currencies. Revenue growth is driven by the new perimeter, strong international growth, and Farm Faes's solid performance, which offset the lower contribution from bilastine in Japan. EBITDA grew by 17% compared with 2025, having included the costs of the SIFI restructuring. Excluding these costs, growth would have been +20%. thousands of € 9M 2026 9M 2025 Change Net revenue 551,942 440,953 25% Other operating income 11,602 13,046 -11% Total revenue 563,544 453,999 24% Cost of sales -182,913 -153,572 19% Gross profit on sales 380,631 300,427 27% Staff costs -126,343 -89,445 41% Other operating expenses -129,927 -104,621 24% Gains/(losses) on fixed assets 0 174 -100% EBITDA 124,361 106,535 17% Depreciation, amortisation and impairment -29,884 -18,646 60% Operating profit 94,477 87,889 7% Financial result -7,156 -1,085 - Profit before tax 87,321 86,804 1% Income tax -13,037 -13,179 -1% Consolidated profit 74,284 73,625 1% Profit attributable to the parent company 74,131 73,561 1%
Page 15
We reaffirm our 2026 guidance following a strong performance over the first nine months 2026 REVENUE EBITDA 2026* Key growth drivers for 2026 +17% / +19% +28% / +31% NET DEBT 2026 < 2x EBITDA ∕ Driving growth in strategic international markets, particularly Latin America, to offset the impact of the loss of exclusivity (LOE) for the bilastine licence in Japan. ∕ Full integration of SIFI and Edol’s operations into the Group. ∕ Generation of commercial synergies by strengthening the presence in the prescription market and the omnichannel approach established in the Group’s wholly-owned subsidiaries. ∕ Favourable comparative base in the final quarter of 2026 following the absorption in Q4 2025 of the majority of the M&A costs associated with the acquisitions. vs 627 M€, 2025 *Including the remaining one-off costs from Derio 15 vs 118 M€, 2025
Page 16
Q&A
Page 17
LEGAL DISCLAIMER This presentation has been prepared and published by the Faes Farma Group and is provided solely for information purposes. This presentation is not a prospectus and does not constitute an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing, or an offer to sell or purchase Faes Farma securities. The information contained in this presentation has not been verified by independent sources and some of the information is presented in summary form. No representations or warranties, whether express or implied, are made by the Faes Farma Group, or by its directors, officers, employees or representatives, regarding the fairness, accuracy, completeness or correctness of the information or opinions expressed in this document, and these should not be relied upon. No member of the Faes Farma Group, nor its respective directors, officers, employees or representatives, shall accept any liability (whether for negligence or otherwise) for any loss, damage, cost or prejudice, whether direct or consequential, arising from the use of this presentation or its contents, or arising in any other way in connection with the presentation, except in respect of any liability for fraud, and they disclaim all liability, whether direct or indirect, express or implied, contractual, tortious, regulatory or otherwise, in relation to the accuracy or completeness of the information or the opinions contained in this document, or any errors, omissions or inaccuracies contained in this presentation. Faes Farma does not guarantee the accuracy of the information contained in this presentation, nor that it is complete. The information contained herein has been obtained from sources considered reliable by Faes Farma, but Faes Farma makes no representation or warranty as to its completeness or accuracy, in particular with regard to data provided by third parties. This presentation contains information and forward-looking statements regarding Faes Farma, S.A. Such statements include financial projections and estimates, together with their underlying assumptions, which do not constitute historical facts. In this regard, whilst Faes Farma S.A. considers the expectations reflected in such statements to be reasonable, it should be noted that the information and forward-looking statements are subject to risks and uncertainties, whether known or unknown, which could cause the group’s business performance to differ from that expressed or implied and affect their realisation.
Page 18
Appendix *Minor variations due to reorganisation in line with accounting standards Breakdown of revenue €M 9M 2026 9M 2025 Var % Iberia 186.6 170.1 10% Pharma Spain 131.7 133.3 -1% Prescription 87.2 87.9 -1% Bilastine RX 12.6 14.7 -15% Calcifediol 32.3 31.3 3% Mesalazine 5.1 5.1 -2% Other 37.3 36.7 2% Healthcare & Consumer 44.4 45.3 -2% Portugal Pharma 55.0 36.8 49% Faes Farma Portugal 27.2 24.9 9% Laboratorio Edol 27.8 11.9 - International (excl. licenses) 216.6 123.4 76% LATAM Subsidiaries 91.3 77.6 18% Central America & Dominican Rep. 25.7 21.3 21% Colombia 22.8 20.1 14% Chile 14.3 13.3 7% Mexico 14.2 10.3 37% Ecuador 9.0 7.8 15% Peru 3.0 2.7 13% Other 2.4 2.1 14% ROW (excl. SIFI) 42.6 39.2 9% ROW Exports 27.1 25.2 8% Faes Gulf 5.1 4.8 6% Italy (Colpharma) 9.7 8.5 13% Nigeria 0.7 0.5 26% SIFI 82.6 6.6 Licenses 83.3 99.2 -16% Bilastine 59.0 76.3 -23% Other Products 24.3 22.9 6% Animal Nutrition & Health 68.6 58.3 18% Iberia 68.1 57.8 18% LATAM Subsidiaries 0.6 0.5 12% Other 0.5 0.4 6% Exchange Rate Variation 7.9 2.6 205% TOTAL REVENUE 563.5 454.0 24% Figures are rounded *